However, the sharp demand for these products and the lack of FDA approval of compounded GLP-1 is raising concerns about the safety, effectiveness, and consistency of these medications, which have grown popular for weight loss
The following table describes GLP-1 receptor agonists, their dosing frequency and key pharmacokinetic parameters: Cautions and Contraindications Adverse Effects Acute pancreatitis (rare) Injection site reactions Gastrointestinal disturbances (nausea, vomiting, diarrhoea dehydration and possible renal impairment) Increase in pancreatic enzymes: lipase and amylase (dulaglutide, tirzepatide and semaglutide) Cholecystitis and cholelithiasis Delayed gastric emptying (semaglutide, exenatide, dulaglutide, tirzepatide (diminishes over time)) Increased heart rate Diabetic retinopathy complications (semaglutide, particularly in insulin-treated patients with known diabetic retinopathy) Interactions GLP-1 receptor agonists do not interact via cytochrome P450 , but delayed gastric emptying may alter drug absorption
Trump says Medicare, Medicaid won't cover weight loss drugs President Donald Trump's administration says Medicare and Medicaid will not pay for GLP-1 drugs when used for weight loss
ArticlePubMed 15
-1775582746855.png)
